Latest Press Releases
Read the latest official press releases and stock market announcements from Meyka.
BRISTOL MYERS SQUIBB RECEIVES POSITIVE CHMP OPINION FOR PERIOPERATIVE REGIMEN OF NEOADJUVANT OPDIVO® (NIVOLUMAB) AND CHEMOTHERAPY FOLLOWED BY SURGERY AND ADJUVANT OPDIVO FOR RESECTABLE NON-SMALL CELL LUNG CANCER IN PATIENTS WITH TUMOR CELL PD-L1
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--BMS RECEIVES POSITIVE CHMP OPINION FOR PERIOPERATIVE REGIMEN OF NEOADJUVANT OPDIVO AND CHEMOTHERAPY FOLLOWED BY SURGERY AND ADJUVANT OPDIVO.
AKESO ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN THE PHASE III CLINICAL TRIAL OF CADONILIMAB FOR ADJUVANT TREATMENT OF HIGH-RISK RECURRENT HEPATOCELLULAR CARCINOMA
HONG KONG , MARCH 5, 2025 /PRNEWSWIRE/ -- AKESO, INC. (9926. HK) ("AKESO" OR THE "COMPANY") IS PLEASED TO ANNOUNCE THE COMPLETION OF PATIENT ENROLLMENT FOR ITS PHASE III REGISTRATIONAL CLINICAL TRIAL (COMPASSION-22/AK104-306) EVALUATING CADONILIMAB, THE WORLD'S FIRST PD-1/CTLA-4 BISPECIFIC ANTIBODY INDEPENDENTLY DEVELOPED BY THE COMPANY, AS AN ADJUVANT TREATMENT FOR HEPATOCELLULAR CARCINOMA (HCC) WITH HIGH RECURRENCE RISK FOLLOWING CURATIVE RESECTION OR ABLATION.
TALON METALS TO OPTION ITS BOULDERDASH AND ROLAND NICKEL-COPPER TARGETS IN MICHIGAN TO LUNDIN MINING
L'ANSE, MICHIGAN--(NEWSFILE CORP. - MARCH 5, 2025) - TALON METALS CORP. (TSX: TLO) (OTC PINK: TLOFF) ("TALON" OR THE "COMPANY") IS PLEASED TO ANNOUNCE THAT IT HAS ENTERED INTO AN EXCLUSIVITY AGREEMENT WITH LUNDIN MINING CORPORATION ("LUNDIN MINING") AS THE PARTIES NEGOTIATE AN EARN-IN AGREEMENT (THE "OPTION AGREEMENT") PURSUANT TO WHICH LUNDIN MINING MAY ACQUIRE UP TO A 70% OWNERSHIP INTEREST IN THE BOULDERDASH AND ROLAND EXPLORATION TARGETS (THE "OPTIONED PROPERTIES"), WHICH ARE IN CLOSE PROXIMITY TO LUNDIN MINING'S EAGLE MINE. LUNDIN MINING HAS ADVANCED TALON US$5 MILLION (THE "ADVANCE PAYMENT") TO, AMONG OTHER THINGS, COMMENCE DRILLING ON THE OPTIONED PROPERTIES AS SOON AS THE OPTION AGREEMENT IS ENTERED INTO.
TROPION-LUNG12 PHASE 3 TRIAL INITIATED EVALUATING DATROWAY® AS PART OF ADJUVANT REGIMEN FOR PATIENTS WITH EARLY-STAGE NON-SMALL CELL LUNG CANCER AT HIGH RISK OF RELAPSE
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--THE FIRST PATIENT HAS BEEN DOSED IN THE TROPION-LUNG12 PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT DATROWAY® (DATOPOTAMAB DERUXTECAN) PLUS RILVEGOSTOMIG OR RILVEGOSTOMIG MONOTHERAPY VERSUS STANDARD OF CARE IN PATIENTS WITH STAGE 1 ADENOCARCINOMA NON-SMALL CELL LUNG CANCER (NSCLC) AFTER COMPLETE SURGICAL RESECTION WHO ARE CTDNA-POSITIVE OR HAVE OTHER HIGH RISK PATHOLOGICAL FEATURES. DATROWAY IS A SPECIFICALLY ENGINEERED TROP2 DIRECTE.
IO BIOTECH COMPLETES ENROLLMENT IN PHASE 2 TRIAL OF ITS INVESTIGATIONAL, OFF-THE-SHELF THERAPEUTIC CANCER VACCINE, IO102-IO103, AS NEOADJUVANT/ADJUVANT TREATMENT FOR PATIENTS WITH RESECTABLE MELANOMA OR HEAD AND NECK CANCER
-- ENROLLMENT COMPLETED AHEAD OF SCHEDULE -- -- INITIAL DATA EXPECTED IN 2025 --
MERCK'S KEYTRUDA® (PEMBROLIZUMAB) APPROVED IN CHINA IN COMBINATION WITH CHEMOTHERAPY AS NEOADJUVANT TREATMENT, THEN CONTINUED AS MONOTHERAPY AFTER SURGERY AS ADJUVANT TREATMENT FOR PATIENTS WITH RESECTABLE STAGE II, IIIA OR IIIB NSCLC
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--MERCK (NYSE: MRK), KNOWN AS MSD OUTSIDE OF THE UNITED STATES AND CANADA, TODAY ANNOUNCED KEYTRUDA, MERCK'S ANTI-PD-1 THERAPY, HAS BEEN APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) IN CHINA IN COMBINATION WITH PLATINUM-CONTAINING CHEMOTHERAPY AS NEOADJUVANT TREATMENT AND THEN CONTINUED AS MONOTHERAPY AS ADJUVANT TREATMENT AFTER SURGERY FOR PATIENTS WITH RESECTABLE STAGE II, IIIA, OR IIIB NON-SMALL CELL LUNG CANCER (NSCLC). “WHILE THERE HAVE BEEN.
HOOKIPA PHARMA DOSES FIRST PATIENTS WITH ESEBA-VEC AS ADJUVANT THERAPY IN PHASE 2 INVESTIGATOR LEAD TRIAL FOR HEAD & NECK CANCER
STUDY DONE IN COLLABORATION WITH MEMORIAL SLOAN KETTERING AND LED BY DR. WINSTON WONG, HEAD AND NECK ONCOLOGIST AND DR. ALAN HO, CHIEF OF THE HEAD AND NECK ONCOLOGY SERVICE
U.S. FOOD AND DRUG ADMINISTRATION APPROVES PERIOPERATIVE TREATMENT OF NEOADJUVANT OPDIVO® (NIVOLUMAB) AND CHEMOTHERAPY FOLLOWED BY SURGERY AND ADJUVANT SINGLE-AGENT OPDIVO FOR RESECTABLE NON-SMALL CELL LUNG CANCER (NSCLC)
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHECKMATE--U.S. FDA APPROVES PERIOPERATIVE TREATMENT OF NEOADJUVANT OPDIVO (NIVOLUMAB) AND CHEMOTHERAPY FOLLOWED BY SURGERY AND ADJUVANT SINGLE-AGENT OPDIVO.
ASTELLAS INITIATES PHASE 3 CLINICAL STUDY OF FEZOLINETANT FOR VMS IN WOMEN WITH BREAST CANCER RECEIVING ADJUVANT ENDOCRINE THERAPY
- HIGHLIGHT 1™ STUDY TO EVALUATE FEZOLINETANT FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS IN WOMEN WITH STAGE 0-3 HORMONE RECEPTOR POSITIVE BREAST CANCER RECEIVING ADJUVANT ENDOCRINE THERAPY - TOKYO , AUG. 27, 2024 /PRNEWSWIRE/ -- ASTELLAS PHARMA INC. (TSE: 4503, PRESIDENT AND CEO: NAOKI OKAMURA, "ASTELLAS") TODAY ANNOUNCED DOSING OF THE FIRST PATIENT IN THE HIGHLIGHT 1™ PHASE 3 PIVOTAL STUDY FOR FEZOLINETANT, AN INVESTIGATIONAL ORAL, NONHORMONAL COMPOUND BEING STUDIED FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS (VMS) IN WOMEN WITH BREAST CANCER RECEIVING ADJUVANT ENDOCRINE THERAPY. BREAST CANCER IS THE MOST COMMON CANCER IN WOMEN GLOBALLY, WITH APPROXIMATELY 2.3 MILLION NEW CASES IN 2022.1 HOT FLASHES AND NIGHT SWEATS, ALSO KNOWN AS VMS, ARE RECOGNIZED AS THE MOST PROMINENT SIDE EFFECT OF ADJUVANT ENDOCRINE THERAPIES USED IN THE TREATMENT OF BREAST CANCER.
GOODYEAR NAMES MAMATHA CHAMARTHI CHIEF DIGITAL OFFICER AND WILL ROLAND CHIEF MARKETING OFFICER
AKRON, OHIO , JULY 30, 2024 /PRNEWSWIRE/ -- THE GOODYEAR TIRE & RUBBER COMPANY (NASDAQ: GT) TODAY ANNOUNCED THAT MAMATHA CHAMARTHI HAS BEEN NAMED SENIOR VICE PRESIDENT AND CHIEF DIGITAL OFFICER, AND WILL ROLAND HAS BEEN NAMED SENIOR VICE PRESIDENT AND CHIEF MARKETING OFFICER, BOTH REPORTING TO CHIEF EXECUTIVE OFFICER AND PRESIDENT MARK STEWART, EFFECTIVE AUGUST 1. "IT'S IMPERATIVE THAT WE UNDERSTAND OUR CUSTOMERS ON A DEEPER LEVEL AND BOTH WILL AND MAMATHA ALLOW US TO LEVERAGE DATA AND CONSUMER INSIGHTS TO TRANSFORM HOW WE MEET CUSTOMER NEEDS," SAID STEWART.
NIDEC ANNOUNCES FINANCIAL RESULTS FOR FISCAL FIRST QUARTER ENDED JUNE 30, 2024
KYOTO, JAPAN--(BUSINESS WIRE)--NIDEC CORPORATION (TOKYO: 6594) (OTC US: NJDCY) TODAY ANNOUNCED ITS CONSOLIDATED RESULTS UNDER THE INTERNATIONAL FINANCIAL REPORTING STANDARDS (“IFRS”) FOR THE THREE-MONTH PERIOD ENDED JUNE 30, 2024. THE HIGHLIGHTS ARE AS FOLLOWS: CONSOLIDATED NET SALES AND OPERATING PROFIT STOOD AT RECORD HIGHS UNDER THE NEW MANAGEMENT. OPERATING PROFIT INCREASED DUE TO A SHIFT TO A HIGHLY PROFITABLE BUSINESS PORTFOLIO IN THE SMALL PRECISION MOTORS, AND THE RECORDING OF GAINS ON.
NIDEC ANNOUNCES THE DISPOSAL OF TREASURY STOCK THROUGH THIRD-PARTY ALLOTMENT IN LINE WITH THE CONTINUATION OF THE PERFORMANCE SHARE PLAN
KYOTO, JAPAN--(BUSINESS WIRE)--NIDEC CORPORATION (TOKYO:6594; OTC US: NJDCY) (“NIDEC” OR THE “COMPANY”) TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS RESOLVED TO DISPOSE TREASURY STOCK THROUGH THIRD-PARTY ALLOTMENT (THE “DISPOSAL OF TREASURY STOCK”) AT A MEETING HELD ON JULY 23, 2024. 1. OUTLINE OF THE DISPOSAL OF TREASURY STOCK 1. DATE OF DISPOSAL AUGUST 7, 2024 2. CLASS AND TOTAL NUMBER OF SHARES TO BE DISPOSED OF 381,600 SHARES OF COMMON STOCK A) BOARD INCENTIVE PLAN TRUST ACCOUNT: 26.
NEW PUBLICATION SHOWS DECISIONDX®-SCC IDENTIFIES HIGH-RISK SQUAMOUS CELL CARCINOMA PATIENTS WHO ARE LIKELY TO BENEFIT FROM ADJUVANT RADIATION THERAPY AND THOSE WHO CAN CONSIDER DEFERRING TREATMENT BASED ON BIOLOGICAL RISK OF METASTASIS
FRIENDSWOOD, TEXAS--(BUSINESS WIRE)---- $CSTL #CSTL--CASTLE ANNOUNCED THE PUBLICATION OF A STUDY DEMONSTRATING THE IMPACT OF THE DECISIONDX-SCC TEST IN GUIDING ADJUVANT RADIATION THERAPY DECISION-MAKING.